Guiding the path of treatment for individual cancer patients
Eutropics’ PraediCare Dx™ platform provides a biomarker technology for accelerating drug discovery and development.
PraediCare Dx™
Eutropics is advancing personalized medicine by providing novel, predictive diagnostic tests that are uniquely accurate in guiding patient cancer treatments.
Innovative leading cancer treatment response predictors
Demonstrated medical utility in blood cancers
CLIA certified tests for Acute Myeloid Leukemia
Validated tests for Chronic Lymphocytic Leukemia